These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15011408)

  • 21. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease: making the diagnosis, selecting drug therapies.
    Scharre DW; Mahler ME
    Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hallucinatory symptoms in Parkinson's disease during treatment with anti-parkinsonian drugs].
    Nagano O; Takauchi S; Nishitani H; Miyoshi K
    Rinsho Shinkeigaku; 1986 May; 26(5):464-70. PubMed ID: 3742899
    [No Abstract]   [Full Text] [Related]  

  • 24. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug-induced cranial myoclonus.
    Gupta A; Lang AE
    Mov Disord; 2010 Oct; 25(13):2264-5. PubMed ID: 20740488
    [No Abstract]   [Full Text] [Related]  

  • 26. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilateral subthalamic nucleus stimulation results in reversal of alopecia in Parkinson's disease.
    Yamada K; Goto S
    Parkinsonism Relat Disord; 2004 Aug; 10(6):353-5. PubMed ID: 15261876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F; López-Ariztegui N
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
    Lacombe E; Khaindrava V; Melon C; Oueslati A; Kerkerian-Le Goff L; Salin P
    Neurobiol Dis; 2009 Oct; 36(1):116-25. PubMed ID: 19615446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug-induced dementia (author's transl)].
    Sternon J
    Rev Med Brux; 1981 Jun; 2(6):569-72. PubMed ID: 7268262
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa: long-term impact on Parkinson's disease.
    Br Med J (Clin Res Ed); 1981 Feb; 282(6262):417-8. PubMed ID: 6780051
    [No Abstract]   [Full Text] [Related]  

  • 37. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
    Goetz CG; Wuu J; Curgian L; Leurgans S
    Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 40. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
    Zoldan J; Friedberg G; Weizman A; Melamed E
    Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.